CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy

BACKGROUND: Combination treatment with chemotherapy and immune checkpoint inhibitors (ICIs) has demonstrated meaningful clinical benefit to patients. However, chemotherapy-induced damage to the immune system can potentially diminish the efficacy of chemotherapy/ICI combinations. Trilaciclib, a highl...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Immunother Cancer
Главные авторы: Lai, Anne Y, Sorrentino, Jessica A, Dragnev, Konstantin H, Weiss, Jared M, Owonikoko, Taofeek K, Rytlewski, Julie A, Hood, Jill, Yang, Zhao, Malik, Rajesh K, Strum, Jay C, Roberts, Patrick J
Формат: Artigo
Язык:Inglês
Опубликовано: BMJ Publishing Group 2020
Предметы:
Clinical/Translational Cancer Immunotherapy
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7534680/
https://ncbi.nlm.nih.gov/pubmed/33004541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000847
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы